clinical trial · NCT01180790
Safety, Tolerability, and Antiviral Activity of ACH-0141625 or Placebo in Combination With Peginterferon and Ribavirin in Hepatitis C Virus (HCV) Positive Participants
Alexion Pharmaceuticals, Inc.·phase2·completed·n = 122
Hepatitis CACH-0141625 (Sovaprevir)ACH-0141625 (Sovaprevir)ACH-0141625 (Sovaprevir)PlaceboPegylated Interferon alpha-2aRibavirin
brief summary
Evaluate safety, tolerability, and antiviral response of ACH-0141625 compared to standard of care in hepatitis C virus (HCV)-positive participants.
started
Sep 1, 2010
primary completion
Mar 1, 2012
completion
Apr 1, 2013
last updated
Aug 30, 2023
official title
A Phase IIa, Randomized, Double-blind (Participant and Investigator Blind, Sponsor Open), Placebo-controlled Trial to Evaluate the Safety, Tolerability, and Antiviral Activity of Oral ACH-0141625 in Combination With Pegylated Interferon Alpha-2a and Ribavirin in Two Segments, After 28 Days of Dosing and, Subsequently, After 12 Weeks of Dosing in Participants With Chronic Hepatitis C Virus Genotype 1
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol